Thorgerdur Palsdottir

Publications
CV
Public outreach and news

Articles

Article: CANCER. 2025;131(16):e70045
Detectable prostate-specific antigen after radiotherapy for clinically localized prostate cancer
Falagario UG; Pellegrino F; Abbadi A; Bjornebo L; Valdman A; Eriksson MH; Zelic R; Carrieri G; Gandaglia G; Briganti A; Montorsi F; Aly M; Palsdottir T; Eklund M; Nordstrom T; Gronberg H; Akre O; Wiklund P; Lantz A
Journal article: JOURNAL OF UROLOGY. 2025;214(2):238
A Comparison of Stockholm3, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm3 Multiethnic SEPTA Trial (vol 213, pg 590, 2025)
Lazarovich A; Vigneswaran H; Palsdottir T; Eklund M; Discacciati A; Nordstrom T; Hubbard RA; Perlis N; Abern MR; Moreira DM; Yonover P; Chow AK; Watts K; Liss MA; Thoreson GR; Abreu AL; Sonn GA; Plym A; Wiklund F; Gronberg H; Murphy AB; Eggener S
Article: EUROPEAN UROLOGY ONCOLOGY. 2025;8(4):1078-1086
Epidemiology of High-risk Biochemical Recurrence After Primary Prostate Cancer Treatment
Falagario UG; Pellegrino F; Bjornebo L; Abbadi A; Martini A; Valdman A; Conteduca V; Carrieri G; Gandaglia G; Briganti A; Montorsi F; Palsdottir T; Eklund M; Nordstrom T; Aly M; Gronberg H; Tewari A; Akre O; Lantz A; Wiklund P
Journal article: JOURNAL OF UROLOGY. 2025;213(5S):e1233
SEQUENTIAL SERIAL PROSTATE CANCER RISK STRATIFICATION WITH PSA, STOCKHOLM3, MRI, AND THE SWOP RISK CALCULATOR FOR BIOPSY SELECTION
Palsdottir T; Gronberg H; Falagario UG; Nordstrom T; Soderback H; Vigneswaran H
Journal article: JOURNAL OF UROLOGY. 2025;213(5S):e687
ARE WE MISSING AGGRESSIVE CANCER WITH PSA SCREENING ALONE? BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY: EVIDENCE FROM THE STHLM3 TRIAL
Vigneswaran H; Palsdottir T; Micoli C; Tilki D; Lin D; Cooperberg M; Eggener S; Moller A; Aly M; Akre O; Wiklund P; Egevad L; Gronberg H; Nordstrom T; Eklund M
Journal article: JOURNAL OF UROLOGY. 2025;213(5S):e155
A COMPARISON OF STOCKHOLM3, SERUM BIOMARKERS, AND RISK CALCULATORS TO PREDICT PROSTATE CANCER IN A DIVERSE COHORT: EVALUATION OF THE STOCKHOLM3 MULTI-ETHNIC SEPTA TRIAL
Lazarovich A; Vigneswaran H; Palsdottir T; Eklund M; Discacciati A; Nordstrom T; Hubbard RA; Perlis N; Abern MR; Moreira DM; Yonover P; Chow AK; Watts K; Liss MA; Thoreson GR; Labreu A; Sonn GA; Plym A; Wiklund F; Gronberg H; Murphy AB; Eggener S
Journal article: JOURNAL OF UROLOGY. 2025;213(5S):e1232
THE ROLE OF THE STOCKHOLM 3 TEST BEFORE CONFIRMATORY BIOPSIES FOR PROSTATE CANCER PATIENTS ENROLLED IN ACTIVE SURVEILLANCE: RESULTS FROM THE STHLM3 AS NORDCAP STUDY
Giudici N; Scuderi S; Palsdottir T; Nordstrom T; Eklund M; Jensby EF; Borre M; Pedersen BG; Gronberg H; Sorensen KD; Kjosavik SR; Lantz A
Article: JOURNAL OF UROLOGY. 2025;213(5):590-599
A Comparison of Stockholm3, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm3 Multiethnic SEPTA Trial
Lazarovich A; Vigneswaran H; Palsdottir T; Eklund M; Discacciati A; Nordstrom T; Hubbard RA; Perlis N; Abern MR; Moreira DM; Yonover P; Chow AK; Watts K; Liss MA; Thoreson GR; Abreu AL; Sonn GA; Plym A; Wiklund F; Gronberg H; Murphy AB; Eggener S
Article: ECLINICALMEDICINE. 2025;82:103191
Evaluating the performance of existing tools to predict clinically significant prostate cancer in men with indeterminate lesions on biparametric MRI and development of a novel multiplex model: a prospective cohort study
Abbadi A; Eklund M; Lantz A; Discacciati A; Bjornebo L; Palsdottir T; Engel JC; Jaderling F; Falagario U; Gronberg H; Nordstrom T
Article: EUROPEAN UROLOGY ONCOLOGY. 2025;8(2):435-443
Diagnostic Effects of Omitting Systematic Biopsies in Prostate Cancer Screening
Engel JC; Eklund M; Jaderling F; Palsdottir T; Falagario U; Discacciati A; Nordstrom T
Journal article: UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. 2025;43(3):76
A COMPARISON OF STOCKHOLM3, SERUM BIOMARKERS, AND RISK CALCULATORS TO PREDICT PROSTATE CANCER IN A DIVERSE COHORT: EVALUATION OF THE STOCKHOLM3 MULTI-ETHNIC SEPTA TRIAL
Lazarovich A; Vigneswaran H; Palsdottir T; Eklund M; Discacciati A; Nordström T; Hubbard R; Perlis N; Abern M; Moreira D; Yonover P; Chow A; Watts K; Liss M; Thoreson G; Abreu A; Sonn G; Plym A; Wiklund F; Grönberg H; Murphy A; Eggener S
Article: JOURNAL OF CLINICAL ONCOLOGY. 2024;42(32):3806-3816
Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial
Vigneswaran HT; Eklund M; Discacciati A; Nordstrom T; Hubbard RA; Perlis N; Abern MR; Moreira DM; Eggener S; Yonover P; Chow AK; Watts K; Liss MA; Thoreson GR; Abreu AL; Sonn GA; Palsdottir T; Plym A; Wiklund F; Gronberg H; Murphy AB
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2024;116(9):1459-1465
Prostate cancer incidence and mortality in men exposed to α1-adrenergic receptor antagonists
Bjornebo L; Razdan S; Discacciati A; Palsdottir T; Aly M; Nordstrom T; Eklund M; Lundon D; Gronberg H; Tewari A; Wiklund P; Kyprianou N; Lantz A
Article: EUROPEAN UROLOGY OPEN SCIENCE. 2024;66:26-32
Cost Analysis of Prostate Cancer Care Using a Biomarker-enhanced Diagnostic Strategy with Stockholm3
McLeod OD; Palsdottir T; Walz J; Tilki D; Briganti A; Stabile A; Vigmostad MN; Mortezavi A; Elyan A; Dudderidge T; Govers T; Gronberg H; Vigneswaran H
Journal article: EUROPEAN UROLOGY. 2024;85:s1692-s1693
Stockholm3 validation in a multi-Ethnic cohort for ProsTAte cancer (SEPTA) detection: A multicentered, prospective trial
Vigneswaran HT; Eklund M; Discacciati A; Nordstrom T; Hubbard RA; Perlis N; Abern M; Moreira D; Eggener S; Yonover P; Chow A; Watts K; Liss M; Thoreson G; Abreu AL; Sonn GA; Palsdottir T; Plym A; Wiklund F; Gronberg H; Murphy AB
Journal article: EUROPEAN UROLOGY. 2024;85:s1674-s1675
Stockholm3 to predict post-operative risk and biochemical recurrence after radical prostatectomy: Evidence from the STHLM3 trial
Vigneswaran HT; Palsdottir T; Gronberg H; Nordstrom T; Egevad L; Eklund M
Journal article: EUROPEAN UROLOGY. 2024;85:s336-s337
Cost effectiveness of prostate cancer testing incorporating Stockholm3 and MRI versus standard of care
Mcleod O; Palsdottir T; Walz J; Tilki D; Briganti A; Stabile A; Vigmostad MN; Mortezavi A; Elyan A; Dudderidge T; Gronberg H; Vigneswaran HT
Journal article: EUROPEAN UROLOGY. 2024;85:s1676-s1677
Using a biomarker test to diagnose prostate cancer in older men; PSA values, MRIand biopsy results
Vigmostad MN; Vigneswaran HT; Gilje B; Kjosavik S; Palsdottir T
Journal article: EUROPEAN UROLOGY. 2024;85:s411-s412
Prostate cancer testing in Stockholm; comparing compliance to follow up of men with elevated PSA vs elevated Stockholm3 in clinical practice between 2018 to 2020
Palsdottir T; Vigneswaran H; Gronberg H; Nordstrom T
Article: EUROPEAN UROLOGY OPEN SCIENCE. 2024;61:29-36
The Capio Prostate Cancer Center Model for Prostate Cancer Diagnostics-Real-world Evidence from 2018 to 2022
Palsdottir T; Soderback H; Jaderling F; Bergman M; Vigneswaran H; Gronberg H
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2024;42(4_SUPPL):295
The Capio Prostate Cancer Center model for prostate cancer diagnostics using Stockholm3, MRI, and targeted biopsies: Real-world evidence from 2018 to 2022
Palsdottir T; Soderback H; Jaderling F; Bergman M; Gronberg H
Journal article: ANNALS OF ONCOLOGY. 2023;34:s1577
The Capio Prostate Cancer Center model for prostate cancer diagnostics using Stockholm3, MRI and targeted biopsies: Real-world evidence from 2018 to 2022
Vigneswaran H; Soderback H; Jaderling F; Bergman M; Gronberg H; Palsdottir T
Article: EUROPEAN UROLOGY FOCUS. 2023;9(3):455-462
External Validation of the Rotterdam Prostate Cancer Risk Calculator and Comparison with Stockholm3 for Prostate Cancer Diagnosis in a Swedish Population-based Screening Cohort
Palsdottir T; Gronberg H; Hilmisson A; Eklund M; Nordstrom T; Vigneswaran HT
Journal article: INVESTIGATIVE UROLOGY. 2023;209(Supplement 4):e997
PD38-11 THE STOCKHOLM3 PROSTATE CANCER SCREENING TRIAL (STHLM3): AN INTERIM ANALYSIS OF MORTALITY RESULTS AFTER 6.5 YEARS OF FOLLOW-UP
Micoli C; Crippa A; Discacciati A; Palsdottir T; Vigneswaran H; Aly M; Adolfsson J; Lindberg J; Wiklund P; Thompson J; Brandberg Y; Clements M; Egevad L; Grönberg H; Nordström T; Eklund M
Journal article: INVESTIGATIVE UROLOGY. 2023;209(Supplement 4):e1044
PD39-02 THE CAPIO S:T GORAN MODEL FOR PROSTATE CANCER DIAGNOSIS USING STOCKHOLM3, MAGNETIC RESONANCE IMAGING AND TARGETED BIOPSIES
Palsdottir T; Grönberg H; Vigneswaran H; Söderbäck H
Journal article: EUROPEAN UROLOGY. 2023;83:s1266-s1267
The Stockholm3 prostate cancer screening trial (STHLM3): An interim analysis of mortality results after 6.5 years of follow-up
Micoli C; Crippa A; Discacciati A; Vigneswaran H; Palsdottir T; Clements M; Aly M; Adolfsson J; Fredrik W; Wiklund P; James T; Lindberg J; Gronberg H; Egevad L; Nordstrom T; Eklund M
Journal article: EUROPEAN UROLOGY. 2023;83:s1293-s1294
External validation of the Rotterdam Prostate Cancer Risk Calculator (RPCRC) and comparison to Stockholm3 for prostate cancer diagnosis in a Swedish population-based screening cohort
Palsdottir T; Gronberg H; Hilmisson A; Eklund M; Nordstrom T; Vigneswaran H
Journal article: EUROPEAN UROLOGY. 2023;83:s107-s108
A0072 The Capio S:t Göran model for prostate cancer diagnosis using Stockholm3, magnetic resonance imaging and targeted biopsies
Palsdottir T; Söderbäck H; Vigneswaran H; Grönberg H
Article: EUROPEAN UROLOGY OPEN SCIENCE. 2022;44:69-75
Digital Rectal Examination in Stockholm3 Biomarker-based Prostate Cancer Screening
Andersson J; Palsdottir T; Lantz A; Aly M; Gronberg H; Egevad L; Eklund M; Nordstrom T
Article: EUROPEAN UROLOGY OPEN SCIENCE. 2022;41:1-7
External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort
Engel JC; Palsdottir T; Ankerst D; Remmers S; Mortezavi A; Chellappa V; Egevad L; Gronberg H; Eklund M; Nordstrom T
Article: JAMA ONCOLOGY. 2022;8(7):1019-1026
Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality
Bjornebo L; Nordstrom T; Discacciati A; Palsdottir T; Aly M; Gronberg H; Eklund M; Lantz A
Journal article: INVESTIGATIVE UROLOGY. 2022;207(Supplement 5):e41
PD03-02 LONG-TERM EFFECTS OF 5Α-REDUCTASE INHIBITORS ON PROSTATE CANCER MORTALITY - A LARGE POPULATION-BASED PROSPECTIVE STUDY
Björnebo L; Nordström T; Discacciati A; Palsdottir T; Aly M; Grönberg H; Eklund M; Lantz A
Article: EUROPEAN UROLOGY OPEN SCIENCE. 2022;38:32-39
A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study
Walden M; Aldrimer M; Lagerlof JH; Eklund M; Gronberg H; Nordstrom T; Palsdottir T
Journal article: EUROPEAN UROLOGY. 2022;81:s561-s562
A0362 Long-term effects of 5α-reductase inhibitors on prostate cancer mortality: A large population-based prospective study
Björnebo L; Nordström T; Discacciati A; Palsdottir T; Aly M; Grönberg H; Eklund M; Lantz A
Journal article: EUROPEAN UROLOGY OPEN SCIENCE. 2021;33:s216-s217
P011 External validation of the Rotterdam Prostate Cancer Risk Calculator and the Prostate Biopsy Collaborative Group Risk Calculator in a Swedish population-based screening cohort
Engel JC; Palsdottir T; Ankerst D; Remmers S; Mortezavi A; Chellappa V; Egevad L; Grönberg H; Eklund M; Nordström T
Article: PROSTATE CANCER AND PROSTATIC DISEASES. 2021;24(2):457-464
Biomarker discrimination and calibration with MRI-targeted biopsies: an analysis with the Stockholm3 test
Vigneswaran HT; Palsdottir T; Olsson H; Haug ES; Picker W; Loffeler S; Gronberg H; Eklund M; Nordstrom T
Article: EUROPEAN UROLOGY FOCUS. 2021;7(3):546-553
Head-to-head Comparison of Conventional, and Image- and Biomarker-based Prostate Cancer Risk Calculators
Mortezavi A; Palsdottir T; Eklund M; Chellappa V; Murugan SK; Saba K; Ankerst DP; Haug ES; Nordstrom T; Tilki D
Article: EUROPEAN UROLOGY OPEN SCIENCE. 2021;24:11-16
Identifying Prostate Cancer Among Men with Lower Urinary Tract Symptoms
Nordstrom T; Engel JC; Bergman M; Egevad L; Aly M; Eklund M; Palsdottir T; Gronberg H
Article: SCANDINAVIAN JOURNAL OF UROLOGY. 2020;54(1):1-6
Lower urinary tract symptoms (LUTS) are not associated with an increased risk of prostate cancer in men 50-69 years with PSA ≥3 ng/ml
Engel JC; Palsdottir T; Aly M; Egevad L; Gronberg H; Eklund M; Nordstrom T
Article: EUROPEAN UROLOGY ONCOLOGY. 2019;2(5):490-496
A Unified Prostate Cancer Risk Prediction Model Combining the Stockholm3 Test and Magnetic Resonance Imaging
Palsdottir T; Nordstrom T; Aly M; Jaderling F; Clements M; Gronberg H; Eklund M
Article: PLOS ONE. 2019;14(6):e0218280
Are Prostate Specific-Antigen (PSA) and age associated with the risk of ISUP Grade 1 prostate cancer? Results from 72 996 individual biopsy cores in 6 083 men from the Stockholm3 study
Palsdottir T; Nordstrom T; Aly M; Lindberg J; Clements M; Egevad L; Gronberg H; Eklund M
Article: BMJ OPEN. 2019;9(3):e027958
The impact of different prostate-specific antigen (PSA) testing intervals on Gleason score at diagnosis and the risk of experiencing false-positive biopsy recommendations: a population-based cohort study
Palsdottir T; Nordstrom T; Karlsson A; Gronberg H; Clements M; Eklund M
Article: JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION. 2017;24(5):950-957
E-Science technologies in a workflow for personalized medicine using cancer screening as a case study
Spjuth O; Karlsson A; Clements M; Humphreys K; Ivansson E; Dowling J; Eklund M; Jauhiainen A; Czene K; Gronberg H; Sparen P; Wiklund F; Cheddad A; Palsdottir P; Rantalainen M; Abrahamsson L; Laure E; Litton J-E; Palmgren J
Show more

All other publications

Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2024;42(4_SUPPL):262
Stockholm3 validation in a multi-ethnic cohort for prostate cancer (SEPTA) detection: A multicentered, prospective trial.
Vigneswaran HT; Eklund M; Discacciati A; Nordstrom T; Hubbard RA; Perlis N; Abern M; Moreira D; Yonover PM; Chow A; Watts K; Liss MA; Thoreson GR; Abreu AL; Sonn GA; Palsdottir T; Wiklund F; Gronberg H; Murphy AB
Conference publication: JOURNAL OF UROLOGY. 2023;209:E997-E998
THE STOCKHOLM3 PROSTATE CANCER SCREENING TRIAL (STHLM3): AN INTERIM ANALYSIS OF MORTALITY RESULTS AFTER 6.5 YEARS OF FOLLOW-UP
Micoli C; Crippa A; Discacciati A; Palsdottir T; Vigneswaran H; Aly M; Adolfsson J; Lindberg J; Wiklund P; Thompson J; Brandberg Y; Clements M; Egevad L; Gronberg H; Nordstrom T; Eklund M
Conference publication: JOURNAL OF UROLOGY. 2023;209:E1044-E1045
THE CAPIO S:T GORAN MODEL FOR PROSTATE CANCER DIAGNOSIS USING STOCKHOLM3, MAGNETIC RESONANCE IMAGING AND TARGETED BIOPSIES
Palsdottir T; Gronberg H; Vigneswaran H; Soderback H
Conference publication: EUROPEAN UROLOGY. 2023;83:S107-S108
The Capio S:t Goran model for prostate cancer diagnosis using Stockholm3, magnetic resonance imaging and targeted biopsies
Palsdottir T; Soderback H; Vigneswaran H; Gronberg H
Conference publication: SCANDINAVIAN JOURNAL OF UROLOGY. 2023;58:23-24
Can Stockholm3 predict post-operative risk (CAPRA-S score) using evidence from the STHLM3 Radical Prostatectomy Cohort?
Palsdottir T
Conference publication: JOURNAL OF UROLOGY. 2022;207(5):E41
LONG-TERM EFFECTS OF 5A-REDUCTASE INHIBITORS ON PROSTATE CANCER MORTALITY - A LARGE POPULATION-BASED PROSPECTIVE STUDY
Bjornebo L; Nordstrom T; Discacciati A; Palsdottir T; Aly M; Gronberg H; Eklund M; Lantz A
Letter: HAEMATOLOGICA. 2022;107(3):740-743
Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen - a real world study on patients diagnosed in Sweden 2007-2017
Albertsson-Lindblad A; Palsdottir T; Smedby KE; Weibull CE; Glimelius I; Jerkeman M
Conference publication: EUROPEAN UROLOGY. 2022;81:S561-S562
Long-term effects of 5α-reductase inhibitors on prostate cancer mortality: A large population-based prospective study
Bjornebo L; Nordstrom T; Discacciati A; Palsdottir T; Aly M; Gronberg H; Eklund M; Lantz A
Conference publication: BLOOD. 2020;136:3-4
Nationwide Investigation of Patient Trajectories in Mantle Cell Lymphoma - Initial Data from the Swedish MCL Complete Project
Jerkeman M; Palsdottir T; Glimelius I; Albertsson-Lindblad A; Weibull C; Ellin F; Sonnevi K; Lewerin C; Brandefors L; Smedby KE
Doctoral thesis: 2019
Risk prediction in prostate cancer diagnostics : current challenges and improvements
Palsdottir T

Employments

Affiliated to Research, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 2024-2027

Degrees and Education

Degree Of Doctor Of Philosophy, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 2019

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI